Key result
Watchman proves noninferior to warfarin for stroke, systemic embolism, and cardiovascular death.
Why the study?
The PROTECT AF study was conducted to determine whether percutaneous left atrial appendage closure with the Watchman device was noninferior to warfarin for stroke prevention in atrial fibrillation.
Does percutaneous left atrial appendage closure with the Watchman device prevent stroke, systemic embolism, and cardiovascular death in patients with nonvalvular atrial fibrillation compared to warfarin?
RCT (n=707)
2:1
Yes
Does percutaneous left atrial appendage closure with the Watchman device prevent stroke, systemic embolism, and cardiovascular death in patients with nonvalvular atrial fibrillation compared to warfarin?
Percutaneous left atrial appendage closure with the Watchman device is noninferior to systemic anticoagulation with warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
LAA closure noninferior to warfarin for AF stroke prevention; leaves open optimal patient selection and long-term device safety in broader populations.
Background: The multicenter PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation. Methods and results: Patients (n = 707) with nonvalvular atrial fibrillation and at least 1 risk factor (age >75 years, hypertension, heart failure, diabetes, or prior stroke/transient ischemic attack) were randomized to either the Watchman device (n = 463) or continued warfarin (n = 244) in a 2:1 ratio. After device implantation, warfarin was continued for ≈45 days, followed by clopidogrel for 4.5 months and lifelong aspirin. Study discontinuation rates were 15.3% (71/463) and 22.5% (55/244) for the Watchman and warfarin groups, respectively. The time in therapeutic range for the warfarin group was 66%. The composite primary efficacy endpoint included stroke, systemic embolism, and cardiovascular death, and the primary analysis was by intention to treat. After 1588 patient-years of follow-up (mean 2.3 ± 1.1 years), the primary efficacy event rates were 3.0% and 4.3% (percent per 100 patient-years) in the Watchman and warfarin groups, respectively (relative risk, 0.71; 95% confidence interval, 0.44%–1.30% per year), which met the criteria for noninferiority (probability of noninferiority >0.999). There were more primary safety events in the Watchman group (5.5% per year; 95% confidence interval, 4.2%–7.1% per year) than in the control group (3.6% per year; 95% confidence interval, 2.2%–5.3% per year; relative risk, 1.53; 95% confidence interval, 0.95–2.70). Conclusions: The “local” strategy of left atrial appendage closure is noninferior to “systemic” anticoagulation with warfarin. PROTECT AF has, for the first time, implicated the left atrial appendage in the pathogenesis of stroke in atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Mohan et al. (2013) conducted an RCT in nonvalvular atrial fibrillation (n=707). Watchman Left Atrial Appendage System vs. warfarin was evaluated on stroke, systemic embolism, and cardiovascular death (RR 0.71, 95% CI 0.44-1.30, p=probability of noninferiority >0.999). Left atrial appendage closure with the Watchman device was noninferior to warfarin for stroke, systemic embolism, and cardiovascular death.
Synapse has enriched 10 related papers. Consider them for comparative context: